Oxford GlycoSciences Plc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who started this subject	3/12/2003 9:26:02 AM
From: nigel bates	of 469

Impacts the value of the OGS proteomics patents ? Message 18688901 As part of the new venture, Beckman Coulter plans to release several new proteomics-related instruments this spring. One such product is the ProteomeLab PF 2D Protein Fractionation System, an automated, two-dimensional chromatographic system that fractionates high- and low-abundance proteins from complex cell lysates. The system separates proteins first by pI and then by hydrophobicity; one and two-dimensional maps of the sample can then be generated using Beckman Coulter's ProteomeLab PF 2D software. Chapman explains that the PF 2D system is the first of its kind on the market. "Nobody has successfully commercialized an automated fractionation system," Chapman says. "2-D gels are still the primary mechanism that people have been using to try to fractionate thousands of proteins," he adds. And strategic marketing manager John Hobbs notes that the PF 2D offers several advantages over traditional two-dimensional gels: greater dynamic range, higher reproducibility, better quantitative precision, and amenability to automation...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next